Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935556 · ClinicalTrials.gov registry record
Characterization and Epigenetics of Post-Partum Preeclampsia
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 12
- Enrollment target
NCT02935556 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 12 participants.
The verdict
NCT02935556 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This study will recruit women with post partum pre-eclampsia and match them to controls without postpartum pre-eclampsia to identify an epigenetic signature that is specific to women with post partum pre-eclampsia to help characterize the underlying pathophysiology of post partum pre-eclampsia.
Interventions
- OTHER no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2022-03-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935556
The ClinicalTrials.gov registry entry for NCT02935556 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which no intervention is the first listed.
NCT02935556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935556 about?
NCT02935556 is a clinical study titled "Characterization and Epigenetics of Post-Partum Preeclampsia". This study will recruit women with post partum pre-eclampsia and match them to controls without postpartum pre-eclampsia to identify an epigenetic signature that is specific to women with post partum pre-eclampsia to help characterize the underlying pathophysiology of post partum pre-eclampsia.
What is the current status of trial NCT02935556?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2017-02-01. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT02935556?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT02935556?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.